The cellular immunotherapy of viral infection.
Viral infections remain a major problem for the patient who has undergone a stem cell transplant and the introduction of increasingly more intensive SCT regimens suggests that this will remain a significant concern for the immediate future. Advances in basic immunology have led to an improved understanding of how immune responses control individual viral infections and this information is now being directly applied to patient care with encouraging results. The application of cellular immunotherapy to the immunocompromised patient is one of the most exciting areas of clinical medicine and offers the prospect of significant clinical impact.
Moss
P A H
PA
Cancer Research UK Institute for Cancer Studies, The University of Birmingham and University Hospitals NHS Trust, Birmingham, UK. p.moss@bham.ac.uk
Cobbold
M
M
Craddock
C
C
D000818:Animals; D016207:Cytokines / Q000378:metabolism; D003587:Cytomegalovirus / Q000276:immunology / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000276:immunology / Q000628:therapy; D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000628:therapy; D006680:HLA Antigens / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000502:physiology; D006801:Humans; D016867:Immunocompromised Host; D016219:Immunotherapy, Adoptive; D017708:Leukocyte Transfusion; D008212:Lymphocyte Depletion / Q000009:adverse effects; D051379:Mice; D033581:Stem Cell Transplantation; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000637:transplantation; D014775:Virus Activation; D014777:Virus Diseases / Q000276:immunology / Q000628:therapy*
D016207:Cytokines; D006680:HLA Antigens